Joining Ofev® (nintedanib), Boehringer Ingelheim (BI) has gained another respiratory asset - BBT-877 - for the treatment of fibrosing interstitial lung diseasesfrom Bridge Biotherapeutics. For a total potential deal value of up to €1145 M (US$1284.6 M), the two companies will initially focus on developing the compound for the treatment of idiopathic pulmonary fibrosis. The deal marks BI’s third this month, having already signed deals with Yuhan and AMAL therapeutics.